Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc
Bullboard Posts
User Avatar Image
(296)
•••
Comment by inthnoon Dec 07, 2010 8:25am
514 Views
Post# 17810810

RE: 15% Gain What happened to it?

RE: 15% Gain What happened to it?Nothing to worry about as it is just the stockhouse feed that is messed up...I have seen this before.....no trades reversed and look at the volume numbers....don't make any sense...Just part of yesterdays feed that is showing up....

this is actually pre-market for oncy which shows oncy up in the premarket
Featured Commentary: Ten Investments to Hedge Inflation





Company News and Commentary for ONCY



Read more ONCY News & Commentary
Subscribe







/www.nasdaq.com/images/capterra/bg_160ad.png") no-repeat scroll 0% 0% transparent; font-family: Arial,Helvetica,sans-serif; font-size: 11px; padding: 0pt;">
Business Software Finder
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">Accounting Software
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">Banking Software
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">Budgeting Software
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">Contract Software
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">CRM Software
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">Document Software
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">Investment Software
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">Project Mgmt Software
  • /www.nasdaq.com/images/capterra/g_bullet.png") no-repeat scroll 0pt 0.4em transparent; padding-left: 8px; margin: 0pt;">Purchasing Software

Oncolytics Biotech, Inc. (ONCY) Pre-Market Trading

Pre-Market Charts |After Hours Charts
Dec. 6, 2010 Market Close: $ 5.84
Pre-Market Last:
Net / % Change		 $ 5.99
.15 (2.57%)		 Pre-Market High: $ 5.99
Pre-Market Volume: 100 Pre-Market Low: $ 5.99
Learn more about the Pre-Market trading session.

Trade Detail

Pre-Market
Time (ET)		 Pre-Market
Price		 Pre-Market
Share Volume
08:01


Read more: https://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=ONCY&mkttype=pre#ixzz17QqZgiM7
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities